Bavarian Nordic Submits Data to Extend Mpox Vaccine Use to Adolescents

The move aims to address the rising mpox cases among younger populations, following WHO's emergency declaration.

Bavarian Nordic seeks European approval to extend its mpox vaccine, Imvanex, to adolescents aged 12-17.
The submission follows interim study results showing similar immune responses and safety profiles in adolescents and adults.
WHO declared the mpox outbreak a public health emergency, with the new clade 1b strain impacting teenagers and young children.
Bavarian Nordic has donated 215,000 doses to Africa CDC and plans further trials for younger children in Congo and Uganda.
The company aims to produce up to 7.5 million doses next year, contingent on securing contracts.